Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations
NCT ID: NCT04814472
Last Updated: 2021-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
34 participants
INTERVENTIONAL
2021-05-16
2021-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of two parts:
Part 1: A randomized, open-label, 3-period, 6-sequence, complete crossover study with at least 3-day washout between treatment periods comparing oral solution formulation to tablet formulation.
Part 2: A randomized, open-label, 4-period, 4-sequence, complete crossover study with at least 3-day washout between treatment periods evaluating single ascending doses of tablet formulation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Solution vs. Tablet Formulation
There will be 3 treatments, each single dose administered based on the treatment sequence with at least a 3 day washout between treatments:
Treatment A: 750 mg BLD-0409 oral solution formulation (solution) under fasting conditions.
Treatment B: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fasting conditions.
Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fed conditions.
BLD-0409
Randomized to active product.
Tablet Formulation Dose Proportionality
There will be 4 treatments, each single dose administered under fed conditions (standard meal) based on the treatment sequence with at least a 3 day washout between treatments:
Treatment A: 250 mg BLD-0409 tablet formulation (1 x 250 mg tablet).
Treatment B: 500 mg BLD-0409 tablet formulation (2 x 250 mg tablet).
Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablet).
Treatment D: 1000 mg BLD-0409 tablet formulation (4 x 250 mg tablet).
BLD-0409
Randomized to active product.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BLD-0409
Randomized to active product.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age and Gender
1. Male and female participants 18-55 years of age (inclusive) at the time of signing the PICF.
Diagnosis and disease characteristics
2. Participants must be in good general health, in the opinion of the Investigator, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening, and/or before administration of the initial dose of study drug.
3. Participants must have clinical laboratory values within normal ranges or \< 1.2 times upper limit of normal (ULN) as specified by the testing laboratory.
4. Body mass index (BMI) 18 to ≤ 32 kg/m2.
Reproductive Considerations
5. Use of acceptable contraception.
6. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. Females not of childbearing potential must be surgically infertile or post-menopausal (defined as cessation of regular menstrual periods for at least 12 months), confirmed by follicle-stimulating hormone (FSH) level \> 40 mIU/mL at Screening.
Informed Consent
7. Participants must provide signed informed consent prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site.
Exclusion Criteria
1. Recent (less than 6 weeks) wound, or presence of an ongoing non-healing skin wound.
2. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will complete the study per protocol.
3. Active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia.
4. Serious local or systemic infection within 1 month of Screening requiring antibiotic treatment or history of recurrent infections.
5. Surgery within the past 3 months prior to the first study drug administration determined by the Investigator to be clinically relevant.
Diagnostic Assessments
6. Positive for human immunodeficiency virus (HIV) antibody or antigen.
7. Positive hepatitis C virus (HCV) antibody or positive hepatitis B surface antigen (HBsAg).
8. Systolic blood pressure (BP) \> 150 mmHg or \< 90 mmHg or diastolic BP \> 90 mmHg or \< 50 mmHg at Screening with one repeat allowed per the Investigator's discretion at Screening and Day -1 (Period 1).
9. Heart rate \< 40 beats per minute (bpm) or \> 100 bpm at Screening.
10. Prolonged QT interval corrected by Fridericia's formula (QTcF) (\> 450 ms for males and \> 470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the Investigator.
11. Females with heavy menstruating cycles and borderline-low iron studies.
Prior Therapy
12. All prescription and over the counter medications (including herbal medications), except for non-estrogen contraceptives, are prohibited within 7 days prior to the first study drug administration and throughout the entire duration of the study.
13. Any estrogen-containing products, e.g., contraceptives, patch, cream, implants within 14 days prior to the first study drug administration.
Prior/Concurrent Clinical Study Experience
14. Administration of investigational product in another study within 30 days prior to the first study drug administration, or five half-lives, whichever is longer.
Other Exclusions
15. Significant weight loss or gain between Screening and first study drug administration.
16. Blood donation or significant blood loss within 60 days prior to the first study drug administration.
17. Plasma donation within 7 days prior to the first study drug administration.
18. Females who are pregnant or breastfeeding.
19. Diets that could alter metabolism (i.e., high protein, Slim Fast®, Nutrisystem®, etc.) within 7 days prior first study drug administration.
20. History or presence of alcohol or drug abuse (including recreational marijuana use) within the 1 year prior to the first study drug administration, and unwillingness to be totally abstinent during the dosing period.
21. Positive urine drug screen/alcohol breath test at Day -1 (admission).
22. Intake of alcohol or caffeine-containing products from 48 hours before first study drug administration through the EOS visit.
23. Active smokers and users of nicotine-containing products.
24. Failure to satisfy the Investigator of fitness to participate for any other reason.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Blade Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Argent, MD
Role: PRINCIPAL_INVESTIGATOR
Scientia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scientia Clinical Research
Randwick, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B-0409-102
Identifier Type: -
Identifier Source: org_study_id